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Instillation of intravesical bacillus Calmette-Guérin (BCG) is an effective treatment for non-muscle
invasive bladder cancer (NMIBC). The high incidence of side effects may limit its tolerability in pa-
tients. Local side effects including cystitis and hematuria are common but generally self-limiting. Bladder
contractures are a rare but serious consequence of BCG treatment. In this case, an 82 year-old male
developed BCG reactivation and subsequent bladder contractures following transurethral resection of the
prostate (TURP) three years post-BCG. To our knowledge, this is the ﬁrst reported case of BCG reactivation
post-TURP leading to the rare but serious effect of bladder contractures.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bladder cancer is a common malignancy and is conﬁned to the
mucosa or submucosa in 75% of cases.1 It is treated with a
combination of transurethral resection (TUR) and adjuvant intra-
vescical chemotherapy or BCG immunotherapy. Intravesical BCG is
an effective treatment for NMIBC compared to TUR and intra-
vesical chemotherapy, or TUR alone, and has been shown to
prevent cancer recurrence, and may even delay tumor progres-
sion.1 BCG therapy is associated with a high incidence of side
effects that commonly occur during induction or the ﬁrst 6 months
of maintenance treatment.2 Serious adverse effects occur in the
minority of patients with the incidence of bladder contractures
being less than 1%.3
Case presentation
In October 2007, an 82 year-old male presented for investigation
of painless macroscopic hematuria on a background of BPH and
emphysema. Initial investigations included urine cytology, urine
culture, TRUS and CT of the abdomen and pelvis. Laboratory in-
vestigations were unremarkable, while imaging results demon-
strated an enlarged prostate measuring 130 cc. Diagnostic
cystoscopy conducted in the same month demonstrated a lesion onia).
serve Rd, St Leonards, NSW
Inc. This is an open access article uthe right bladder wall that was resected. Histology showed a high-
grade papillary bladder cancer. His repeat cystoscopy 6 weeks later
was clear.
On surveillance cystoscopy 6 months later, an area of erythema
suggestive of carcinoma-in-situ (CIS) near the right ureteric oriﬁce
was noted and resected; this was conﬁrmed on histology. Given his
tumor proﬁle, the patient was commenced on a 6-weeks course of
induction BCG therapy in March 2008. The patient completed six
rounds of induction intravesical BCG therapy that was well toler-
ated. No maintenance therapy was given.
The patient underwent TURP in July 2008, following an episode
of urinary retention in conjunction with a history of obstructive
voiding symptoms. At the time of the TURP, the bladder looked
macroscopically normal with a good capacity and no sign of con-
tractions. The histology of the prostate specimen showed nodular
hyperplasia of the prostate in addition to granulomatous inﬂam-
mation indicative of the BCG effect. Serial surveillance cystoscopies
and urine cytology were clear.
By late 2010, almost 3 years following BCG therapy, the
patient began experiencing issues with nocturnal frequency and
incontinence. Urine cultures taken were positive for mycobac-
teria. A repeat cystoscopy showed marked inﬂammatory
changes within the bladder, with associated thickened bladder
mucosa; biopsies taken at the time conﬁrmed BCG cystitis. The
patient was commenced on a course of oral Rifampicin, Isoni-
azid and Pyridoxinein in standard doses for a total of 9 months
for reactivation of BCG.
Ongoing daytime frequency and urge incontinence prompted
repeat urine cultures that grew Klebsiella oxytoca and wasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Follow-up cystoscopy in 2012 in which there was no bladder cancer recurrence, but evidence of bladder wall irregularity and inﬂammation. The bladder demonstrated
evidence of ﬁbrosis and poor contractility.
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antibiotic treatment, the patient’s symptoms persisted. Further
investigation with a CT abdomen and pelvis in September 2011
demonstrated marked mural thickening of the bladder with bilat-
eral hydro-ureter and hydronephrosis. Check cystoscopy in the
same month showed signiﬁcant improvement in the inﬂammation,
however, some areas of bullous edema persisted. Biopsies taken at
the time revealed congestion and inﬂammatory cell inﬁltrate, but
no evidence of malignancy. Additionally, repeat urine cultures were
negative forMycobacterium bovis BCG but did show a small numberFigure 2. Bladder biopsy demonstrating inﬂamed stromal tissue with dense chronic
and granulomatous inﬂammatory inﬁltrate.of atypical cells that were considered to be reactive in nature. The
patient was advised to undertake bladder training, wear a urodome
and was commenced on solifenacin succinate.
Repeat urine cultures following the completion of tuberculosis
treatment were all negative for M. bovis, suggesting successful
treatment of his BCG reactivation. However, his symptoms of fre-
quency and urge incontinence persisted despite medication and
behavioral therapy. Subsequent surveillance cystoscopy showed no
cancer recurrence, but did demonstrate bladder irregularity with
multiple septae, diverticuli and evidence of contractures.
Over the next 2 years continued surveillance did not identify a
recurrence of bladder cancer, though the bladder remained ﬁbrotic
and poorly contractile. The patient was not a candidate for surgery
due to his anesthetic risk, thus his ongoing incontinence
was managed with incontinence pads and urodomes indeﬁnitely
(Figs. 1 and 2).
Discussion
The most common side effects of intravesical BCG treatment are
local and transient. As demonstrated in the EORTC Genito-Urinary
Cancers Group Randomized Phase 3 Study, local side effects occur
in 62.8% of patients with the most common being chemical cystitis
(35.0%), frequency (23.6%), bacterial cystitis (23.3%), and macro-
scopic hematuria (22.6%).4 Systemic side effects reported included
malaise (15.5%) and fever (8.1%). Though side effects are a common
occurrence, a reduction in dose or the duration of maintenance
therapy does not signiﬁcantly decrease the incidence of side
effects.4
Granulomatous prostatitis is another common effect of BCG
treatment, caused by mycobacterium contaminated urine. Most
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Isoniazid, Rifampicin and ﬂuoroquinolones.2 While transient local
side effects may be managed symptomatically, more serious
adverse effects such as bladder contractures can result in perma-
nent incontinence, as in this case. BCG-associated bladder con-
tractures are rare and tend to be associated with maintenance
therapy and multiple TURBTs.2 Published cases of bladder con-
tractures post-BCG treatment evidence that this side effect tends to
occur early in the induction phase of treatment.5
In our case, the reactivation of BCG with resultant granuloma-
tous prostatitis and bladder contracture occurred 3 years post-
induction BCG; the patient had not received maintenance BCG.
Further, treatment was initiated at least 2 weeks post-resection in
order to minimize the risk of mycobacterium absorption, in accor-
dance with the International Bladder Cancer Group’s recommen-
dations.2 This case highlights the need for increased vigilance
regarding rare BCG-related adverse effects beyond the induction
period, and in the absence of risk factors.
The incidence of adverse effects may be prevented through
correct catheterization technique, deferral of treatment
following traumatic catheterization or UTI, use of Oﬂoxacin, and
dose reduction in patients with demonstrated intolerance.
Prompt recognition of serious adverse effects requires early
consultation with an infectious disease specialist, and appro-
priate antibiotic treatment. In this case, the consequences of
the BCG reactivation led to a ﬁbrotic, poorly compliant bladder
with persistent frequency and permanent incontinence. Surgical
treatment options were limited in this patient were due to his
anesthetic risk.
This case demonstrates the need for increased awareness of BCG
reactivation in patients undergoing TURP post-BCG. Furthermore,
vigilant monitoring of potential adverse effects is required beyond
the induction phase of treatment, as is demonstrated in this case of
delayed BCG reactivation. The consequences of BCG reactivation areparticularly dire in patients for whom surgical treatment options
are limited.
Conclusion
Delayed reactivation of BCG following TURP is not a well-
described phenomenon. The bladder contractures that may result,
however, can have devastating consequences for the patient.
Though the true risk of such events is difﬁcult to predict, the pos-
sibility of their occurrence and the consequences should be
considered and discussed with patients.
Consent
Consent for the construction and publication of this case reports
was obtained from the patient prior to submission.
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